SCHEMBL719988

SCHEMBL719988

COc1ccc(-n2cc(C=O)c(C(C)C)n2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
NLRP3 Q96P20 1/20 0.56
NPBWR1 P48145 1/20 0.44
MCHR1 Q99705 1/20 0.44
ALDH1A1 P00352 2/20 0.42
ADORA3 P0DMS8 4/20 0.41
PTGS2 P35354 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
POLB P06746 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
CA12 O43570 1/20 0.39
CA9 Q16790 1/20 0.39
MAPKAPK2 P49137 2/20 0.39
ADORA1 P30542 1/20 0.39
MIF P14174 1/20 0.39
CYP2A6 P11509 1/20 0.39
ATM Q13315 1/20 0.39
HDAC1 Q13547 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL719895 0.85 MEN1 (0.50) MEN1KMT2ANLRP3ALDH1A1ADORA3
SCHEMBL16830535 0.82 PTGS2 (0.58) MEN1KMT2ANLRP3ALDH1A1PTGS2
SCHEMBL718901 0.81 MEN1 (0.60) MEN1KMT2ANLRP3ALDH1A1ADORA3
SCHEMBL6035925 0.79 PTGS2 (0.40) MEN1KMT2ANLRP3ALDH1A1ADORA3
SCHEMBL23400080 0.78 MIF (0.44) MEN1KMT2AALDH1A1ADORA3L3MBTL1
SCHEMBL718659 0.77 MEN1 (0.56) MEN1KMT2ANLRP3ALDH1A1ADORA3
SCHEMBL2555928 0.76 MEN1 (0.59) MEN1KMT2ANLRP3ALDH1A1ADORA3
SCHEMBL719455 0.76 MEN1 (0.55) MEN1KMT2ANLRP3ALDH1A1ADORA3
SCHEMBL717648 0.75 L3MBTL1 (0.58) MEN1KMT2ANPBWR1MCHR1ALDH1A1
SCHEMBL718323 0.75 MEN1 (0.54) MEN1KMT2ANLRP3ALDH1A1ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP MEN1 444/4885KMT2A 1298/4885NLRP3 1630/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP MEN1 444/4885KMT2A 1298/4885NLRP3 1630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.